Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for rocuronium (compound)

Name: rocuronium
PubChem Compound ID: 441290
Molecular formula: C32H53N2O4+
Molecular weight: 529.774 g/mol
143558-00-3; Rocuronium; C07556
Name: rocuronium
Name (isomeric): DB00728
Drug Type: small molecule
Rocuronium bromide
Brand: Zemuron, Esmeron
Category: Neuromuscular Nondepolarizing Agents, Skeletal Muscle Relaxants
CAS number: 119302-91-9
Indication: For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Neuromuscular blocking agents are drugs that cause skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of motor end-plate, which leads...
show more »
Mechanism of Action:
Rocuronium acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Rocuronium acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic...
show more »
Absorption: Poorly absorbed from the GI tract.
Protein binding: Approximately 30% bound to human plasma proteins.
Biotransformation: Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.
Route of elimination: Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.
Half Life: The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.
Clearance: 0.25 L/kg/hr [Adults (Ages 27 to 58 years)] 0.21 L/kg/hr [Geriatrics (>=65 yrs)] 0.16 L/kg/hr [Normal ewnal and hepatice function] 0.13 L/kg/hr [Renal transplant patients] 0.13 L/kg/hr [Hepatic dysfunction patients] 0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos] 0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs] 0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]
Toxicity: No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected organisms: Humans and other mammals
Drug interaction:
TobramycinThe agent increases the effect of the muscle relaxant
ColistimethateColistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
NetilmicinThe agent increases the effect of muscle relaxant
GentamicinThe agent increases the effect of muscle relaxant
PiperacillinThe agent increases the effect of the muscle relaxant
show more »